Mingjun Rui

414 total citations
20 papers, 268 citations indexed

About

Mingjun Rui is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Mingjun Rui has authored 20 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Economics and Econometrics. Recurrent topics in Mingjun Rui's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Mingjun Rui is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Mingjun Rui collaborates with scholars based in China, Hong Kong and United Kingdom. Mingjun Rui's co-authors include Hongchao Li, Yingcheng Wang, Ting Zhou, Yao Zhang, Haijing Guan, Aixia Ma, Ye Shang, Xueke Zhang, Xin‐Yuan Guan and Rui Meng and has published in prestigious journals such as Frontiers in Pharmacology, Cancer Epidemiology Biomarkers & Prevention and Head & Neck.

In The Last Decade

Mingjun Rui

16 papers receiving 266 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mingjun Rui China	8	118	96	85	35	27	20	268
Per-Olof Thuresson Switzerland	8	85 0.7×	98 1.0×	97 1.1×	35 1.0×	44 1.6×	22	390
Claudio Faria United States	10	150 1.3×	74 0.8×	71 0.8×	35 1.0×	30 1.1×	32	329
Meaghan Krohe United States	9	109 0.9×	59 0.6×	51 0.6×	20 0.6×	13 0.5×	19	336
S.M. Babineaux United States	6	85 0.7×	109 1.1×	40 0.5×	35 1.0×	43 1.6×	11	397
Costel Chirila United States	13	82 0.7×	138 1.4×	74 0.9×	25 0.7×	35 1.3×	35	423
Edit Remák United Kingdom	10	94 0.8×	132 1.4×	143 1.7×	21 0.6×	53 2.0×	31	336
Saira Khan United States	11	100 0.8×	102 1.1×	21 0.2×	34 1.0×	29 1.1×	43	325
Emelie Andersson Sweden	11	130 1.1×	23 0.2×	78 0.9×	47 1.3×	25 0.9×	27	442
Soo Kien Lo Singapore	7	154 1.3×	146 1.5×	59 0.7×	16 0.5×	15 0.6×	11	329
Chaoyi Zheng United States	10	123 1.0×	64 0.7×	86 1.0×	30 0.9×	95 3.5×	21	352

Countries citing papers authored by Mingjun Rui

Since Specialization

Citations

This map shows the geographic impact of Mingjun Rui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingjun Rui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingjun Rui more than expected).

Fields of papers citing papers by Mingjun Rui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingjun Rui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingjun Rui. The network helps show where Mingjun Rui may publish in the future.

Co-authorship network of co-authors of Mingjun Rui

This figure shows the co-authorship network connecting the top 25 collaborators of Mingjun Rui. A scholar is included among the top collaborators of Mingjun Rui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingjun Rui. Mingjun Rui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yingcheng, et al.. (2025). Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical analysis. Expert Review of Vaccines. 24(1). 1015–1023.

Rui, Mingjun, Yingcheng Wang, & Joyce H. S. You. (2025). Health Economic Evaluations of Circulating Tumor DNA Testing for Cancer Screening: Systematic Review. Cancer Medicine. 14(3). e70641–e70641. 4 indexed citations

Rui, Mingjun, et al.. (2025). Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Patients with Irritable Bowel Syndrome. Digestion. 1–13.

Wang, Yingcheng, et al.. (2025). Health economic evaluations of fecal microbiota transplantation for non-clostridioides difficile related diseases: a systematic review. Health Economics Review. 15(1). 103–103.

Rui, Mingjun, Yingcheng Wang, & Joyce H. S. You. (2025). Novel Noninvasive Tests for Colorectal Cancer Screening – A Cost-Effectiveness Analysis. Cancer Epidemiology Biomarkers & Prevention. 34(7). 1111–1121. 3 indexed citations

Rui, Mingjun, et al.. (2025). HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology. 17. 22800845–22800845.

Rui, Mingjun & Yingcheng Wang. (2024). Comparative effectiveness and cost‐effectiveness of endoscopic nasopharyngectomy versus intensity‐modulated radiotherapy in the treatment of recurrent nasopharyngeal carcinoma: A microsimulation analysis. Head & Neck. 47(2). 529–537. 1 indexed citations

Rui, Mingjun, et al.. (2023). Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis. BioDrugs. 38(1). 157–170. 2 indexed citations

Li, Hongchao, et al.. (2022). Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC. Frontiers in Public Health. 10. 956792–956792. 15 indexed citations

10.

Rui, Mingjun, Zijing Wang, Yao Wu, et al.. (2022). The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China. Frontiers in Pharmacology. 13. 862640–862640. 1 indexed citations

11.

Rui, Mingjun, et al.. (2022). Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China. Journal of Medical Economics. 25(1). 618–629. 30 indexed citations

12.

Rui, Mingjun, et al.. (2022). Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China. Expert Review of Pharmacoeconomics & Outcomes Research. 23(1). 79–87. 2 indexed citations

13.

Wang, Yingcheng, Mingjun Rui, Lan Yang, et al.. (2021). Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US. Frontiers in Public Health. 9. 650392–650392. 10 indexed citations

14.

Zhou, Ting, et al.. (2021). Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. Frontiers in Public Health. 9. 675523–675523. 121 indexed citations

15.

Wang, Yingcheng, et al.. (2021). Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective. Frontiers in Medicine. 8. 658747–658747. 22 indexed citations

16.

Rui, Mingjun, et al.. (2021). Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China. Frontiers in Medicine. 8. 657539–657539. 1 indexed citations

17.

Rui, Mingjun, et al.. (2021). Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Review of Pharmacoeconomics & Outcomes Research. 21(3). 373–380. 25 indexed citations

18.

Rui, Mingjun, et al.. (2021). Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis. Frontiers in Medicine. 8. 4 indexed citations

19.

Rui, Mingjun, et al.. (2020). Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model. Advances in Therapy. 37(9). 3761–3774. 17 indexed citations

20.

Rui, Mingjun & Hongchao Li. (2020). Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non–Small Cell Lung Cancer in China. Clinical Therapeutics. 42(11). 2159–2170.e6. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact